• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    RayzeBio, Inc. - Common Stock (NQ: RYZB )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Feb 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 62.49 (10)
    Ask (Size) 62.54 (3)
    Prev. Close 62.49
    Today's Range N/A - N/A
    52wk Range 18.68 - 62.51
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
    AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
    Via Benzinga
    Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
    From Bristol Myers Squibb
    Via Business Wire

    Performance

    More News

    Read More
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
    Via Benzinga
    Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
    From Bristol Myers Squibb
    Via Business Wire
    Pancreatic Cancer Treatments Poised for Major Advances in 2024
    Via FinancialNewsMedia
    The Best-Performing U.S. IPOs Of 2023
    Via Talk Markets
    IPO watch 2024: Which new stocks will hit the market?
    Via MarketBeat
    Topics Initial Public Offering
    Exposures Securities Market
    Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
    Via Investor's Business Daily
    Cramer Says This 'Inexpensive' Stock Is 'Doing Some Great Things With Aerospace'
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
    Via MarketBeat
    Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
    Via Benzinga
    Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
    Via Benzinga
    Investor Sentiment Improves; Dow Jumps Over 150 Points
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Stocks Extend Gains As Oil Prices Rise
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
    Via Investor's Business Daily
    Why Is RayzeBio (RYZB) Stock Up 100% Today?
    Via InvestorPlace
    RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.
    From Halper Sadeh LLC
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.